Mario Negri Institute For Pharmacological Research
Clinical trials sponsored by Mario Negri Institute For Pharmacological Research, explained in plain language.
-
New combo aims to make large lung cancers treatable with radiation
Disease control TerminatedThis study tested whether adding the immunotherapy drug durvalumab to standard chemotherapy could shrink large stage III lung cancers enough to allow radiation therapy. About 65 patients were planned, but the study was stopped early. The goal was to see if more patients could bec…
Phase: PHASE2 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
Promising combo for breast cancer falls short: trial ends early
Disease control TerminatedThis study tested whether adding ATRA (a vitamin A derivative) to the standard hormone therapy anastrozole could shrink tumors in postmenopausal women with a common type of early breast cancer (HR+/HER2-). The goal was to see if the combination worked better than anastrozole alon…
Phase: PHASE2 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC